Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Waldenstrom Macroglobulinemia × Thalidomide × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 7 Waldenstrom Macroglobulinemia 1 Recurrence 1 Precancerous Conditions 1 Neoplasms, Plasma Cell 1 Medulloblastoma 1 Mastocytosis, Systemic 1 Lymphoma, Mantle-Cell 1 Liver Neoplasms 1 Leukemia, Large Granular Lymphocytic 1 Ependymoma 1 Carcinoma, Hepatocellular 1

Interventions

Rituximab 17 zanubrutinib 13 ibrutinib 10 venetoclax 7 Cyclophosphamide 6 Bendamustine Hydrochloride 6 pirtobrutinib 4 acalabrutinib 4 ixazomib 3 Specimen Handling 3 Sirolimus 3 Magnetic Resonance Spectroscopy 3 Lenalidomide 3 Dexamethasone 3 Bortezomib 3 Biopsy 3 fludarabine phosphate 2 Whole-Body Irradiation 2 Prednisone 2 Peripheral Blood Stem Cell Transplantation 2 Mycophenolic Acid 2 Etoposide 2 Cyclosporine 2 CT-P10 2 Blood Specimen Collection 2 ARQ531 2 talquetamab 1 selinexor 1 pomalidomide 1 pembrolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02844309 2026-02-11

BDH-WM02

Institute of Hematology & Blood Diseases Hospital, China

Phase 4 Completed

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡